News about Quality / GMP

Alembic Pharmaceuticals Receives US FDA Approval for Olopatadine Eye Drops

Alembic Pharmaceuticals Receives US FDA Approval for Olopatadine Eye Drops

Alembic Pharmaceuticals receives final US FDA approval for its olopatadine hydrochloride ophthalmic solution USP, 0.7 per cent, an OTC treatment for itchy eyes.

Quality / GMP | 05/11/2026 | By News Bureau

Dr Reddy's Receives ANVISA Approval for Generic Semaglutide in Brazil

Dr Reddy's Receives ANVISA Approval for Generic Semaglutide in Brazil

Dr Reddy’s Laboratories receives ANVISA marketing authorisation for its generic semaglutide injection for adults with inadequately controlled type 2 diabetes in Brazil.

Quality / GMP | 05/11/2026 | By News Bureau

Moberg Pharma Secures US Patent for Improved MOB-015 Dosing Regimen

Moberg Pharma Secures US Patent for Improved MOB-015 Dosing Regimen

Moberg Pharma secures US patent for an improved dosing regimen of MOB-015, strengthening its intellectual property portfolio through December 2041.

Quality / GMP | 04/11/2026 | By News Bureau

EMA Validates Immunome's Varegacestat Application for Desmoid Tumours

EMA Validates Immunome's Varegacestat Application for Desmoid Tumours

Immunome has secured EMA validation for its varegacestat marketing application for adults with desmoid tumours, supported by positive Phase 3 RINGSIDE trial results.

Quality / GMP | 03/11/2026 | By News Bureau

Granules India's Gagillapur Plant Gets 11 US FDA Observations

Granules India's Gagillapur Plant Gets 11 US FDA Observations

Granules India’s Gagillapur facility has received 11 US FDA observations, with none related to data integrity or cross-contamination.

Quality / GMP | 02/11/2026 | By News Bureau |  130

MSD's Capvaxive Receives Singapore HSA Approval for Adults Aged 18 and Above

MSD's Capvaxive Receives Singapore HSA Approval for Adults Aged 18 and Above

MSD's Capvaxive receives Singapore HSA approval for active immunisation against invasive pneumococcal disease and pneumonia caused by 21 specified serotypes in adults aged 18 and above.

Quality / GMP | 30/10/2026 | By News Bureau |  101

Octant's OCT-980 Receives FDA Orphan Drug Designation for Retinitis Pigmentosa

Octant's OCT-980 Receives FDA Orphan Drug Designation for Retinitis Pigmentosa

Octant is evaluating OCT-980 in a Phase 1b/2 study at US sites, with the aim of developing a potential oral, disease-modifying treatment for RHO-adRP.

Quality / GMP | 29/10/2026 | By News Bureau

Cipla's InvaGen Facility Gets Zero US FDA Form 483 Observations

Cipla's InvaGen Facility Gets Zero US FDA Form 483 Observations

Cipla’s InvaGen facility has received zero Form 483 observations from the US FDA following an inspection.

Quality / GMP | 27/10/2026 | By News Bureau

Alembic Pharma Gets US FDA Final Approval for Otic Suspension

Alembic Pharma Gets US FDA Final Approval for Otic Suspension

Alembic Pharmaceuticals receives US FDA final approval for generic ciprofloxacin and dexamethasone otic suspension, targeting specified ear infections. The product’s US market is valued at USD 110 million.

Quality / GMP | 19/10/2026 | By News Bureau |  103

Cognition Therapeutics Secures US Patent for Zervimesine

Cognition Therapeutics Secures US Patent for Zervimesine

Cognition Therapeutics secures US patent for a novel crystalline form of zervimesine, supporting large-scale manufacturing and planned registrational development for dementia with Lewy bodies.

Quality / GMP | 14/10/2026 | By News Bureau

 
 

 

 

We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.

More information: Privacy Policy

 pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members